Downregulation of mapk/mak/mrk overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus.

MAPK/MAK/MRK overlapping kinase 1 Mammalian target of rapamycin type 1 diabetes mellitus

Journal

Journal of medical biochemistry
ISSN: 1452-8258
Titre abrégé: J Med Biochem
Pays: Serbia
ID NLM: 101315490

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 20 07 2021
accepted: 18 10 2021
entrez: 31 8 2022
pubmed: 1 9 2022
medline: 1 9 2022
Statut: ppublish

Résumé

Type 1 diabetes mellitus (T1DM) is one of the most common endocrine diseases in children. T-cell autoreactivity toward b-cells is controlled by significant changes in metabolism of T cells. Mammalian target of rapamycin (mTOR) is an important intracellular regulator of metabolism and cell growth. MAPK/MAK/MRK overlapping kinase 1 (MOK1) is one of the less known regulators of mTOR. We sought to investigate if MOK1 and mTOR mRNA levels in peripheral blood mononuclear cells (PBMCs) of T1DM pediatric patients are different compared to healthy subjects. This study included 172 adolescents with T1DM and 36 healthy adolescent volunteers designated for control group (CG). MOK1 and mTOR mRNA levels were determined in PBMCs by qPCR. T1DM patients have significant downregulation of MOK1 mRNA levels in PBMCs compared CG (P=0.018), while there was no significant difference in mTOR mRNA levels (P=0.891). Furthermore, in T1DM patients, MOK1 significantly correlated with age, triglycerides and mTOR, while mTOR correlated significantly with BMI and systolic blood pressure. Overweight T1DM subjects had significantly lower MOK1 (P=0.034) and mTOR (P=0.017) mRNA levels, together with significantly higher levels of systolic blood pressure (P<0.001), total cholesterol (P=0.001), LDL-cholesterol (P=0.001) and CRP (P<0.001). Multi - variate analysis showed that MOK1 was independently negatively associated with T1DM when adjusted for sex, age, HDL-C and CRP (OR=0.417 (95%CI: 0.175-0.997), p=0.049). Our study demonstrated for the first time that T1DM is associated with MOK1 downregulation. In addition, downregulation of both mTOR and MOK1 gene expressions was associated with cardiovascular risk factors in overweight T1DM patients. Dijabetes melitus tip 1 (T1DM) jedno je od najčešćih endokrinih oboljenja kod dece. Autoreaktivnost T-ćelija prema b-ćelijama kontroliše se značajnim promenama u metabolizmu T ćelija. Cilj delovanja rapamicina kod sisara je važan unutarćelijski regulator metabolizma i rasta ćelija. MAPK/MAK/MRK preklapajuće kinaze koja se preklapa (MOK1) jedan je od manje poznatih regulatora mTOR-a. Cilj istraživanja je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvi različiti kod pedijatrijskih pacijenata sa T1DM u odnosu na zdrave ispitanike. Ovo istraživanje je obuhvatilo 172 adolescenta sa T1DM i 36 zdravih adolescenata dobrovoljaca koji su činili kontrolnu grupu (CG). Nivoi MOK1 i mTOR mRNA određeni su u PBMC-ima pomoću qPCR-a. Pacijenti sa T1DM imali su značajno niže nivoe iRNK MOK1 u PBMC u odnosu na CG, dok razlike u nivoima iRNK mTOR nisu bile značajne (P = 0,891). Štaviše, kod pacijenata sa T1DM, MOK1 je značajno korelirao sa godinama, trigliceri dima i mTOR, dok je mTOR značajno korelirao sa BMI i sistolnim krvnim pritiskom. Ispitanici sa prekomernom težinom T1DM imali su značajno niže nivoe iRNK MOK1 (P = 0,034) i mTOR (P = 0,017), zajedno sa značajno većim nivoima sistolnog krvnog pritiska (P <0,001), ukupnog holesterola (P = 0,001), LDL-holesterola (P = 0,001) i CRP (P <0,001). Multivarijantna analiza je pokazala da je MOK1 nezavisno negativno povezan sa T1DM kada je prilagođen polu, starosti, HDL-C i CRP (OR = 0,417 (95%CI: 0,175-0,997), p = 0,049). Naša studija je prva koja je pokazala da je T1DM udružen sa nishodnom regulacijom MOK1. Pored toga, snižena regulacija ekspresije gena mTOR i MOK1 bila je povezana sa kardiovaskularnim faktorima rizika kod pacije nata sa T1DM sa prekomernom težinom.

Sections du résumé

Background UNASSIGNED
Type 1 diabetes mellitus (T1DM) is one of the most common endocrine diseases in children. T-cell autoreactivity toward b-cells is controlled by significant changes in metabolism of T cells. Mammalian target of rapamycin (mTOR) is an important intracellular regulator of metabolism and cell growth. MAPK/MAK/MRK overlapping kinase 1 (MOK1) is one of the less known regulators of mTOR. We sought to investigate if MOK1 and mTOR mRNA levels in peripheral blood mononuclear cells (PBMCs) of T1DM pediatric patients are different compared to healthy subjects.
Methods UNASSIGNED
This study included 172 adolescents with T1DM and 36 healthy adolescent volunteers designated for control group (CG). MOK1 and mTOR mRNA levels were determined in PBMCs by qPCR.
Results UNASSIGNED
T1DM patients have significant downregulation of MOK1 mRNA levels in PBMCs compared CG (P=0.018), while there was no significant difference in mTOR mRNA levels (P=0.891). Furthermore, in T1DM patients, MOK1 significantly correlated with age, triglycerides and mTOR, while mTOR correlated significantly with BMI and systolic blood pressure. Overweight T1DM subjects had significantly lower MOK1 (P=0.034) and mTOR (P=0.017) mRNA levels, together with significantly higher levels of systolic blood pressure (P<0.001), total cholesterol (P=0.001), LDL-cholesterol (P=0.001) and CRP (P<0.001). Multi - variate analysis showed that MOK1 was independently negatively associated with T1DM when adjusted for sex, age, HDL-C and CRP (OR=0.417 (95%CI: 0.175-0.997), p=0.049).
Conclusions UNASSIGNED
Our study demonstrated for the first time that T1DM is associated with MOK1 downregulation. In addition, downregulation of both mTOR and MOK1 gene expressions was associated with cardiovascular risk factors in overweight T1DM patients.
Uvod UNASSIGNED
Dijabetes melitus tip 1 (T1DM) jedno je od najčešćih endokrinih oboljenja kod dece. Autoreaktivnost T-ćelija prema b-ćelijama kontroliše se značajnim promenama u metabolizmu T ćelija. Cilj delovanja rapamicina kod sisara je važan unutarćelijski regulator metabolizma i rasta ćelija. MAPK/MAK/MRK preklapajuće kinaze koja se preklapa (MOK1) jedan je od manje poznatih regulatora mTOR-a. Cilj istraživanja je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvi različiti kod pedijatrijskih pacijenata sa T1DM u odnosu na zdrave ispitanike.
Metode UNASSIGNED
Ovo istraživanje je obuhvatilo 172 adolescenta sa T1DM i 36 zdravih adolescenata dobrovoljaca koji su činili kontrolnu grupu (CG). Nivoi MOK1 i mTOR mRNA određeni su u PBMC-ima pomoću qPCR-a.
Rezultati UNASSIGNED
Pacijenti sa T1DM imali su značajno niže nivoe iRNK MOK1 u PBMC u odnosu na CG, dok razlike u nivoima iRNK mTOR nisu bile značajne (P = 0,891). Štaviše, kod pacijenata sa T1DM, MOK1 je značajno korelirao sa godinama, trigliceri dima i mTOR, dok je mTOR značajno korelirao sa BMI i sistolnim krvnim pritiskom. Ispitanici sa prekomernom težinom T1DM imali su značajno niže nivoe iRNK MOK1 (P = 0,034) i mTOR (P = 0,017), zajedno sa značajno većim nivoima sistolnog krvnog pritiska (P <0,001), ukupnog holesterola (P = 0,001), LDL-holesterola (P = 0,001) i CRP (P <0,001). Multivarijantna analiza je pokazala da je MOK1 nezavisno negativno povezan sa T1DM kada je prilagođen polu, starosti, HDL-C i CRP (OR = 0,417 (95%CI: 0,175-0,997), p = 0,049).
Zaključak UNASSIGNED
Naša studija je prva koja je pokazala da je T1DM udružen sa nishodnom regulacijom MOK1. Pored toga, snižena regulacija ekspresije gena mTOR i MOK1 bila je povezana sa kardiovaskularnim faktorima rizika kod pacije nata sa T1DM sa prekomernom težinom.

Autres résumés

Type: Publisher (srp)
Dijabetes melitus tip 1 (T1DM) jedno je od najčešćih endokrinih oboljenja kod dece. Autoreaktivnost T-ćelija prema b-ćelijama kontroliše se značajnim promenama u metabolizmu T ćelija. Cilj delovanja rapamicina kod sisara je važan unutarćelijski regulator metabolizma i rasta ćelija. MAPK/MAK/MRK preklapajuće kinaze koja se preklapa (MOK1) jedan je od manje poznatih regulatora mTOR-a. Cilj istraživanja je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvi različiti kod pedijatrijskih pacijenata sa T1DM u odnosu na zdrave ispitanike.

Identifiants

pubmed: 36042901
doi: 10.5937/jomb0-33220
pii: jomb-41-3-2203282S
pmc: PMC9375534
doi:

Types de publication

Journal Article

Langues

eng

Pagination

282-289

Informations de copyright

2022 Miron Sopić, Ana Ninić, Barbara Ostanek, Dragana Bojanin, Tatjana Milenković, Jelena Munjas, Marija Mihajlović, Jelena Vekić, Janja Marc, Vesna Spasojević-Kalimanovska, published by CEON/CEES.

Déclaration de conflit d'intérêts

Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Références

PLoS One. 2014 Sep 22;9(9):e108470
pubmed: 25243405
FASEB J. 2017 Jul;31(7):2797-2816
pubmed: 28336525
Mol Med. 2010 Jul-Aug;16(7-8):235-46
pubmed: 20386866
Int Rev Immunol. 2015 Jan;34(1):50-66
pubmed: 25019278
J Med Biochem. 2021 Jan 26;40(1):33-40
pubmed: 33584138
Pediatr Res. 2003 May;53(5):830-5
pubmed: 12702748
Curr Opin Immunol. 2011 Dec;23(6):746-53
pubmed: 22051340
Immunogenetics. 1996;44(5):323-30
pubmed: 8781117
Hypertension. 2018 Mar;71(3):457-464
pubmed: 29311254
Diabetes Ther. 2018 Feb;9(1):349-361
pubmed: 29139080
Nat Immunol. 2016 Jan;17(1):104-12
pubmed: 26551880
Int J Clin Exp Pathol. 2015 Jan 01;8(1):127-36
pubmed: 25755699
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Circulation. 2014 Sep 23;130(13):1110-30
pubmed: 25114208
Lancet. 2014 Jan 4;383(9911):69-82
pubmed: 23890997
Circ Res. 2018 Jun 8;122(12):1722-1740
pubmed: 29880500
Nat Rev Dis Primers. 2017 Mar 30;3:17016
pubmed: 28358037
Curr Diab Rep. 2017 May;17(5):24
pubmed: 28303386
Clin Exp Pharmacol Physiol. 2015 Apr;42(4):331-6
pubmed: 25582653
Diabetes Care. 2005 Jan;28(1):186-212
pubmed: 15616254
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
J Med Biochem. 2016 Jan;35(1):34-42
pubmed: 28356862

Auteurs

Miron Sopić (M)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Ana Ninić (A)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Barbara Ostanek (B)

University of Ljubljana, Faculty of Pharmacy, Department of clinical Biochemistry, Slovenia.

Dragana Bojanin (D)

Mother and Child Health Care Institute of Serbia "Dr Vukan Čupić", Biochemical Laboratory, Belgrade.

Tatjana Milenković (T)

Mother and Child Health Care Institute of Serbia "Dr Vukan Čupić", Department of Endocrinology, Belgrade.

Jelena Munjas (J)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Marija Mihajlović (M)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Jelena Vekić (J)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Janja Marc (J)

University of Ljubljana, Faculty of Pharmacy, Department of clinical Biochemistry, Slovenia.

Vesna Spasojević-Kalimanovska (V)

University of Belgrade, Faculty of Pharmacy, Department of Medical Biochemistry.

Classifications MeSH